Franklin M. Berger - 13 Oct 2026 Form 4 Insider Report for Retension Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 13 Oct 2026
Net transaction value: +$120,000
SEC form: 4
Accepted by SEC: 13 Oct 2026, 18:10:58 UTC
Prior SEC filing: 08 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Alex Schwartz, Attorney-in-fact

Filing notes and source

Key filing fact

Franklin M. Berger filed Form 4 for Retension Pharmaceuticals, Inc. on 13 Oct 2026.

Key facts

This page summarizes Franklin M. Berger's Form 4 filing for Retension Pharmaceuticals, Inc..
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Oct 2026, 18:10.

Change

Previous filing in this sequence was filed on 08 Oct 2026.
Current net transaction value: +$120,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001273885 Primary reporting owner

BERGER FRANKLIN M

Relationship: Director
Address: 1104 WEST BROAD STREET, SUITE 1029, FALLS CHURCH
Signature: /s/ Alex Schwartz, Attorney-in-fact
Signature date: 13 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +12,517
Change %
Price
Shares after: 12,517
Date: 13 Oct 2026
Ownership: Direct
Footnotes: F1

No ticker transaction

Common Stock

Purchase

Transaction value: $120,000
Shares: +10,000
Change %
Price: $12.00
Shares after: 10,000
Date: 13 Oct 2026
Ownership: By FMB Research

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Series B Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,517
Change %: -100%
Price
Shares after: 0
Date: 13 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,517
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.